Zentalis Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our principal executive office is located at 10275 Science Center Drive, Suite 200, San Diego, California 92121, where we lease approximately 56,700 square feet and 17,900 square feet of office and laboratory space, respectively, under a lease that expires in September 2032. We believe that our facilities are sufficient to meet our current needs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.